Tag Archives: Diffuse Large B-cell lymphoma

July, 2018

January, 2018

October, 2017

July, 2017

June, 2017

September, 2016

July, 2016

June, 2016

  • 24 June

    Epizyme and Genentech Partner to Assess Drug Combo in NHL

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial to investigate the anti-cancer effects of Epizyme’s EZH2 inhibitor, tazemetostat, …

March, 2016

  • 14 March

    ProNAi’s DLBCL Candidate Awarded FDA Orphan Drug Designation

    VANCOUVER, March 14, 2016 /PRNewswire/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for patients with cancer and hematological diseases, today announced that its oncology drug candidate PNT2258 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse …

April, 2015